Cold Genesys Raises $13.8 Million from Hong Kong-US Investment Firm

Cold Genesys, a California clinical-stage biopharma that is developing a cancer immunotherapy, raised $13.8 million in a Series A financing from Ally Bridge Group. Ally Bridge is a Hong Kong-US investing firm focused on life science. CGI will use the money to complete a Phase II/III trial of CG0070, an engineered oncolytic virus, which is being tested in patients with high-risk carcinoma in situ non-muscle invasive bladder cancer (NMIBC). More details.... Share this with colleagues: // //